O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	20	double
O	20	21	-
O	21	26	blind
O	26	27	,
O	28	35	placebo
O	35	36	-
O	36	46	controlled
O	47	52	study
O	53	63	evaluating
O	64	67	the
O	68	76	efficacy
O	77	79	of
O	80	91	combination
B-intervention	92	102	olanzapine
I-intervention	102	103	,
I-intervention	104	115	ondansetron
I-intervention	116	119	and
I-intervention	120	133	dexamethasone
O	134	137	for
O	138	148	prevention
O	149	151	of
B-condition	152	164	chemotherapy
I-condition	164	165	-
I-condition	165	172	induced
I-condition	173	179	nausea
I-condition	180	183	and
I-condition	184	192	vomiting
O	193	195	in
O	196	204	patients
O	205	214	receiving
O	215	226	doxorubicin
O	227	231	plus
O	232	248	cyclophosphamide
O	248	249	.

O	250	255	Since
O	256	260	most
O	261	263	of
B-location	264	268	Thai
O	269	275	cancer
O	276	284	patients
O	285	294	receiving
O	295	299	high
O	300	310	emetogenic
O	311	323	chemotherapy
O	324	326	do
O	327	330	not
O	331	335	have
O	336	342	access
O	343	345	to
O	346	356	neurokinin
O	356	357	-
O	357	358	1
O	359	360	(
O	360	362	NK
O	362	363	-
O	363	364	1
O	364	365	)
O	366	374	receptor
O	375	386	antagonists
O	387	389	or
O	390	402	palonosetron
O	403	405	as
O	406	417	recommended
O	418	420	by
O	421	434	international
O	435	445	guidelines
O	446	449	for
O	450	462	chemotherapy
O	462	463	-
O	463	470	induced
O	471	477	nausea
O	478	481	and
O	482	490	vomiting
O	491	492	(
O	492	496	CINV
O	496	497	)
O	498	508	prevention
O	508	509	.

O	510	512	We
O	513	520	decided
O	521	523	to
O	524	532	evaluate
O	533	536	the
O	537	545	efficacy
O	546	548	of
O	549	559	olanzapine
O	560	564	with
O	565	568	the
O	569	573	real
O	573	574	-
O	574	578	life
O	579	587	practice
O	588	598	antiemetic
O	599	604	drugs
O	605	616	ondansetron
O	617	620	and
O	621	634	dexamethasone
O	634	635	,
O	636	638	in
O	639	649	prevention
O	650	652	of
O	653	657	CINV
O	658	667	resulting
O	668	672	from
O	673	684	doxorubicin
O	685	689	plus
O	690	706	cyclophosphamide
O	707	714	regimen
O	715	717	in
O	718	723	early
O	723	724	-
O	724	729	stage
O	730	736	breast
O	737	743	cancer
O	744	752	patients
O	752	753	.

O	754	756	In
O	757	761	this
O	762	772	randomized
O	772	773	,
O	774	780	double
O	780	781	-
O	781	786	blind
O	786	787	,
O	788	795	placebo
O	795	796	-
O	796	806	controlled
O	807	812	trial
O	812	813	,
O	814	816	we
O	817	825	compared
O	826	836	olanzapine
O	837	841	with
O	842	843	a
O	844	851	placebo
O	852	854	in
O	855	866	combination
O	867	871	with
O	872	883	ondansetron
O	884	887	and
O	888	901	dexamethasone
O	902	904	in
B-eligibility	905	910	early
I-eligibility	910	911	-
I-eligibility	911	916	stage
I-eligibility	917	923	breast
I-eligibility	924	930	cancer
I-eligibility	931	939	patients
I-eligibility	940	949	receiving
I-eligibility	950	961	doxorubicin
I-eligibility	962	964	60
I-eligibility	965	967	mg
I-eligibility	967	968	/
I-eligibility	968	970	m2
I-eligibility	971	975	plus
I-eligibility	976	992	cyclophosphamide
I-eligibility	993	996	600
I-eligibility	997	999	mg
I-eligibility	999	1000	/
I-eligibility	1000	1002	m2
O	1002	1003	.

O	1004	1007	The
O	1008	1020	intervention
O	1021	1026	group
O	1027	1035	received
O	1036	1046	olanzapine
O	1047	1049	10
O	1050	1052	mg
O	1053	1059	orally
O	1060	1065	while
O	1066	1069	the
O	1070	1077	control
O	1078	1083	group
O	1084	1092	received
O	1093	1094	a
O	1095	1103	matching
B-control	1104	1111	placebo
O	1112	1117	daily
O	1118	1120	on
O	1121	1124	day
O	1125	1126	1
O	1127	1134	through
O	1135	1138	day
O	1139	1140	4
O	1140	1141	.

O	1142	1145	All
O	1146	1154	patients
O	1155	1163	received
O	1164	1175	ondansetron
O	1176	1177	8
O	1178	1180	mg
O	1181	1184	and
O	1185	1198	dexamethasone
O	1199	1201	20
O	1202	1204	mg
O	1205	1218	intravenously
O	1219	1221	30
O	1222	1229	minutes
O	1230	1236	before
O	1237	1249	chemotherapy
O	1250	1264	administration
O	1265	1268	and
O	1269	1273	then
O	1274	1287	dexamethasone
O	1288	1290	10
O	1291	1293	mg
O	1294	1299	daily
O	1300	1306	orally
O	1307	1311	from
O	1312	1315	day
O	1316	1317	1
O	1318	1325	through
O	1326	1329	day
O	1330	1331	4
O	1331	1332	.

O	1333	1336	The
O	1337	1344	primary
O	1345	1353	endpoint
O	1354	1357	was
B-outcome-Measure	1358	1360	no
I-outcome-Measure	1361	1367	nausea
I-outcome-Measure	1368	1372	rate
I-outcome-Measure	1373	1375	in
I-outcome-Measure	1376	1379	the
I-outcome-Measure	1380	1385	early
I-outcome-Measure	1386	1392	period
O	1392	1393	.

O	1394	1397	The
O	1398	1407	secondary
O	1408	1417	endpoints
O	1418	1422	were
B-outcome-Measure	1423	1425	no
I-outcome-Measure	1426	1432	nausea
I-outcome-Measure	1433	1437	rate
I-outcome-Measure	1438	1440	in
I-outcome-Measure	1441	1444	the
I-outcome-Measure	1445	1452	delayed
I-outcome-Measure	1453	1456	and
I-outcome-Measure	1457	1464	overall
I-outcome-Measure	1465	1472	periods
O	1473	1476	and
O	1477	1478	a
B-outcome-Measure	1479	1487	complete
I-outcome-Measure	1488	1496	response
I-outcome-Measure	1497	1498	(
I-outcome-Measure	1498	1500	no
I-outcome-Measure	1501	1509	vomiting
I-outcome-Measure	1510	1513	and
I-outcome-Measure	1514	1516	no
I-outcome-Measure	1517	1520	use
I-outcome-Measure	1521	1523	of
I-outcome-Measure	1524	1530	rescue
I-outcome-Measure	1531	1535	drug
I-outcome-Measure	1535	1536	)
O	1536	1537	.

O	1538	1546	Outcomes
O	1547	1551	were
O	1552	1562	determined
O	1563	1565	by
O	1566	1574	patients
O	1574	1575	'
O	1576	1580	self
O	1580	1581	-
O	1581	1589	reported
O	1590	1595	daily
O	1596	1603	records
O	1604	1606	of
O	1607	1615	episodes
O	1616	1618	of
O	1619	1627	vomiting
O	1628	1630	or
O	1631	1639	retching
O	1639	1640	,
O	1641	1644	use
O	1645	1647	of
O	1648	1654	rescue
O	1655	1662	therapy
O	1663	1666	and
O	1667	1672	daily
O	1673	1679	levels
O	1680	1682	of
O	1683	1689	nausea
O	1690	1695	based
O	1696	1698	on
O	1699	1700	a
O	1701	1707	visual
O	1707	1708	-
O	1708	1716	analogue
O	1717	1722	scale
O	1723	1727	from
O	1728	1731	the
O	1732	1737	first
O	1738	1743	cycle
O	1744	1746	of
O	1747	1759	chemotherapy
O	1759	1760	.

O	1761	1762	A
O	1763	1768	total
O	1769	1771	of
B-total-participants	1772	1774	39
O	1775	1781	female
O	1782	1790	patients
O	1791	1795	were
O	1796	1806	randomized
O	1807	1809	in
O	1810	1811	a
O	1812	1813	1
O	1813	1814	:
O	1814	1815	1
O	1816	1821	ratio
O	1822	1824	to
O	1825	1832	receive
O	1833	1843	olanzapine
O	1844	1845	(
B-intervention-participants	1845	1847	20
O	1848	1856	patients
O	1856	1857	)
O	1858	1860	or
O	1861	1862	a
O	1863	1871	matching
O	1872	1879	placebo
O	1880	1881	(
B-control-participants	1881	1883	19
O	1884	1892	patients
O	1892	1893	)
O	1893	1894	.

O	1895	1896	A
O	1897	1910	significantly
O	1911	1918	greater
O	1919	1929	proportion
O	1930	1932	of
O	1933	1941	patients
O	1942	1950	reported
O	1951	1953	no
B-outcome	1954	1960	nausea
O	1961	1963	in
O	1964	1967	the
O	1968	1978	olanzapine
O	1979	1984	group
O	1985	1989	than
O	1990	1992	in
O	1993	1996	the
O	1997	2004	placebo
O	2005	2010	group
O	2011	2013	in
O	2014	2018	both
O	2019	2022	the
O	2023	2028	early
O	2029	2035	period
O	2036	2037	(
O	2037	2038	0
O	2038	2039	-
O	2039	2041	24
O	2042	2047	hours
O	2048	2053	after
O	2054	2066	chemotherapy
O	2066	2067	)
O	2068	2071	and
O	2072	2075	the
O	2076	2083	overall
O	2084	2090	period
O	2091	2092	(
O	2092	2093	0
O	2093	2094	-
O	2094	2097	120
O	2098	2103	hours
O	2104	2109	after
O	2110	2122	chemotherapy
O	2122	2123	)
O	2123	2124	.

O	2125	2133	Patients
O	2134	2137	who
O	2138	2146	reported
B-outcome	2147	2149	no
I-outcome	2150	2156	nausea
I-outcome	2157	2159	in
I-outcome	2160	2163	the
I-outcome	2164	2169	early
I-outcome	2170	2176	period
O	2177	2186	accounted
O	2187	2190	for
B-iv-bin-percent	2191	2193	50
I-iv-bin-percent	2193	2194	%
O	2195	2198	and
B-cv-bin-percent	2199	2201	10
I-cv-bin-percent	2201	2202	.
I-cv-bin-percent	2202	2203	5
I-cv-bin-percent	2203	2204	%
O	2205	2207	in
O	2208	2211	the
O	2212	2222	olanzapine
O	2223	2228	group
O	2229	2232	and
O	2233	2235	in
O	2236	2239	the
O	2240	2247	placebo
O	2248	2253	group
O	2254	2266	respectively
O	2267	2268	(
O	2268	2269	P
O	2269	2270	=
O	2270	2271	0
O	2271	2272	.
O	2272	2275	008
O	2275	2276	)
O	2276	2277	.

O	2278	2280	In
O	2281	2284	the
B-outcome	2285	2292	overall
I-outcome	2293	2299	period
O	2299	2300	,
B-iv-bin-percent	2301	2303	30
I-iv-bin-percent	2303	2304	.
I-iv-bin-percent	2304	2305	0
I-iv-bin-percent	2305	2306	%
O	2307	2310	and
B-cv-bin-percent	2311	2312	0
I-cv-bin-percent	2312	2313	%
O	2314	2316	of
O	2317	2325	patients
O	2326	2334	reported
B-outcome	2335	2337	no
I-outcome	2338	2344	nausea
O	2345	2347	in
O	2348	2351	the
O	2352	2362	olanzapine
O	2363	2366	and
O	2367	2374	placebo
O	2375	2381	groups
O	2382	2394	respectively
O	2395	2396	(
O	2396	2397	P
O	2397	2398	=
O	2398	2399	0
O	2399	2400	.
O	2400	2403	009
O	2403	2404	)
O	2404	2405	.

O	2406	2408	In
O	2409	2412	the
O	2413	2418	early
O	2419	2425	period
O	2425	2426	,
O	2427	2432	there
O	2433	2436	was
O	2437	2438	a
O	2439	2452	significantly
O	2453	2462	different
B-outcome	2463	2471	complete
I-outcome	2472	2480	response
I-outcome	2481	2485	rate
O	2486	2493	between
O	2494	2497	two
O	2498	2507	treatment
O	2508	2514	groups
O	2514	2515	;
B-iv-bin-percent	2516	2518	75
I-iv-bin-percent	2518	2519	.
I-iv-bin-percent	2519	2520	0
I-iv-bin-percent	2520	2521	%
O	2522	2524	in
O	2525	2528	the
O	2529	2539	olanzapine
O	2540	2545	group
O	2546	2549	and
B-cv-bin-percent	2550	2552	36
I-cv-bin-percent	2552	2553	.
I-cv-bin-percent	2553	2554	8
I-cv-bin-percent	2554	2555	%
O	2556	2558	in
O	2559	2562	the
O	2563	2570	placebo
O	2571	2576	group
O	2577	2578	(
O	2578	2579	P
O	2579	2580	=
O	2580	2581	0
O	2581	2582	.
O	2582	2585	016
O	2585	2586	)
O	2586	2587	.

O	2588	2595	Overall
B-outcome	2596	2605	treatment
I-outcome	2605	2606	-
I-outcome	2606	2613	related
I-outcome	2614	2621	adverse
I-outcome	2622	2628	events
O	2629	2633	were
O	2634	2637	not
O	2638	2651	significantly
O	2652	2661	different
O	2662	2669	between
O	2670	2673	the
O	2674	2677	two
O	2678	2683	study
O	2684	2690	groups
O	2691	2697	except
O	2698	2702	that
O	2703	2713	somnolence
O	2714	2717	was
O	2718	2731	significantly
O	2732	2736	more
O	2737	2743	common
O	2744	2746	in
O	2747	2750	the
O	2751	2761	olanzapine
O	2762	2767	group
O	2768	2772	than
O	2773	2775	in
O	2776	2779	the
O	2780	2787	placebo
O	2788	2793	group
O	2793	2794	.

O	2795	2805	Olanzapine
O	2806	2808	10
O	2809	2811	mg
O	2812	2820	combined
O	2821	2825	with
O	2826	2837	ondansetron
O	2838	2841	and
O	2842	2855	dexamethasone
O	2856	2859	was
O	2860	2864	more
O	2865	2874	effective
O	2875	2879	than
O	2880	2881	a
O	2882	2889	placebo
O	2890	2892	in
O	2893	2903	preventing
O	2904	2908	CINV
O	2909	2918	resulting
O	2919	2923	from
O	2924	2935	doxorubicin
O	2936	2940	plus
O	2941	2957	cyclophosphamide
O	2958	2960	in
O	2961	2966	early
O	2966	2967	-
O	2967	2972	stage
O	2973	2979	breast
O	2980	2986	cancer
O	2987	2995	patients
O	2995	2996	,
O	2997	3007	especially
O	3008	3010	in
O	3011	3014	the
O	3015	3020	first
O	3021	3023	24
O	3024	3029	hours
O	3030	3035	after
O	3036	3048	chemotherapy
O	3049	3063	administration
O	3063	3064	.

O	3065	3068	The
O	3069	3074	short
O	3075	3083	duration
O	3084	3086	of
O	3087	3097	olanzapine
O	3098	3101	was
O	3102	3106	safe
O	3107	3110	and
O	3111	3115	well
O	3116	3125	tolerated
O	3125	3126	.
